Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Hepatology. 2009 Jul;50(1):185–197. doi: 10.1002/hep.22952

Figure 4. CCR2 deficiency inhibits hepatic fibrosis after CCl4 treatment.

Figure 4

WT (n=6) and CCR2-/- (n=6) mice were treated with 12 injections of CCl4 (0.5μl/g). (A, B) Fibrillar collagen deposition was evaluated by Sirius red staining (A) and quantitation (B) after 12 injection of CCl4. (C) Hepatic hydroxyproline content was measured. (D, E) Expression of α-SMA was determined by immunohistochemistry (D) and western blotting (E). (F) Serum ALT levels after 12 injection of CCl4 were measured. *: p<0.05 for CCl4-treated CCR2-/- mice versus CCl4-treated WT mice. Original magnification is ×100 (A, D).